Annals of Internal Medicine · 1983 · 71 citations · 13 references
MedicineOncologyPharmacotherapyChemotherapyMedical OncologyTumor ProgressionCancer ProgressionLung CancerMalignant NeoplasmsRelapsed DiseaseTherapy Response AssessmentChemotherapy Response AssessmentDisease-free Survival AssessmentDurable Clinical ResponseGrowth RatesReinduction TherapySmall Cell Lung Cancer TherapySmall Cell Lung Cancer Treatment
Some patients with small-cell carcinoma of lung can be expected to achieve long-term disease-free survival. However, relapses may occur even after 2 years. Information on the treatment of these patients is sparse, although response rates to "salvage" therapy in patients with progressive disease while receiving treatment are poor. We report six patients who had relapses after more than 2 years in complete remission. Five patients were retreated with chemotherapy including some or all of the drugs in the initial treatment, and four had responses with a median duration of 10 months (range, 2 to 18 months). Thus retreatment with chemotherapy similar to the initial treatment can occasionally achieve second responses persisting up to 1 year or longer. The high incidence of patients who have relapses after 2 years confirms previous data on relatively slow growth rates in small-cell carcinoma.
13
Keynote address on biostatistics and data retrieval.
Marvin Zelen · PubMed · 1973 · 485 citations
Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
Martin H. Cohen, Daniel C. Ihde, Paul A. Bunn et al. · PubMed · 1979 · 180 citations
Medicine, Oncology, Pharmacology +15
F. Anthony Greco, Ronald L. Richardson, James D. Snell et al. · The American Journal of Medicine · 1979 · 118 citations